TCRX

TScan Therapeutics, Inc.

8.74 USD
-0.26 (-2.89%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TScan Therapeutics, Inc. stock is down -2.13% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.

  • HC Wainwright & Co.
    Tue Jun 4, 07:20
    buy
    confirm
  • BTIG
    Thu May 16, 10:10
    buy
    initial